Boehringer Ingelheim agreed to invest $10 billion in U.S. operations through 2028 and join the administration’s TrumpRx.gov purchasing platform in a deal aimed at lowering medicine costs for American patients. The company said the agreement includes an exemption from potential Section 232 tariffs and commits capital to expand research, development and manufacturing capacity in the U.S. Jean‑Michel Boers, president and CEO of Boehringer Ingelheim USA, framed the pact as a dual effort to increase access while strengthening domestic supply chains. The arrangement underscores the administration’s strategy of pairing industrial investment with pricing commitments and will be watched for precedent among other global pharmas.